go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

Sanofi Pasteur MSD Limited

Sanofi Pasteur MSD Limited
Block A, Second Floor, Cookstown Court, Old Belgard Road, Tallaght, Dublin 24,
Telephone: +353 1 468 5600
Fax: +353 1 420 3588
Medical Information Direct Line: +44 (0)1628 587 693
Medical Information e-mail: medinfo@spmsd.com
Medical Information Facsimile: +44 (0)1628 635 072
Summary of Product Characteristics last updated on medicines.ie: 03/10/2011
SPC HBVAXPRO 5mcg

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 03/10/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   31-Aug-2011
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company


  • In section 4.8, Uveitis has been added as an undesirable effect under a new category of Eye Disorder
  • In section 4.4, 'vial stopper' has been deleted and replaced with 'the syringe plunger stopper and tip cap' in the latex warning paragraph
  • In section 9, the date of the last renewal has been updated to 27/4/2011
  • In section 10, the date of revision text is now 08/2011
Updated on 20/07/2011 and displayed until 03/10/2011
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.9 - Overdose
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   01-Mar-2011
Legal Category:   Product subject to medical prescription which may not be renewed (A)

Free-text change information supplied by the pharmaceutical company


  • In section 4.4, latex warning has been added
  • In section 4.9, No case of overdose reported has been changed to there have been reports of administration of higher than recommended dose"
  • In section 6.6, inserted the following text “The vaccine should be inspected visually in order to detect any appearance of precipitate or discolouring of the content prior to administration. If these conditions exist, the product should not be administered. Before use, the syringe should be well shaken”
  • In section 10, the date of the text has been revised from December 2007 to 03/2011
Updated on 28/11/2008 and displayed until 20/07/2011
Reasons for adding or updating:
  • Change to section 6.5 - Nature and contents of container
  • Change to section 8 - MA number
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   12/2007
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

Change to section 6.5 Addition of 20 and 50 pack sizes for prefilled syringe with 2 separate needles presentation.
 
Change to section 8 Addition of new license numbers for new 20 and 50 pack sizes for prefilled syringe with 2 separate needles presentation.
 
Change to section 10 Date of revision updated.
 
Updated on 07/02/2008 and displayed until 28/11/2008
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
Date of revision of text on the SPC:   12/2007
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

Change to section 4.4 - added warning on the potential of apnoea in very premature infants
Change to section 4.8 - added apnoea (in very premature infants)
Updated on 22/08/2006 and displayed until 07/02/2008
Reasons for adding or updating:
  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   08/2006
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

·        Section 1 - update to name

·        Section 2 - words updated for clarification

·        Section 3 - updated to include description of pharmaceutical form

·        Section 4.2 Primary vaccination - the need of the 4th dose at 12 months has been reinforced, when the compressed administration schedule 0, 1, 2 and 12 months is used.

·        Section 4.2 Immunocompromised vaccinees, Revaccination of non-responders and Special dosage recommendation for known of presumed exposure to hepatitis B virus - the recommendations for serologic testing, and administration of additional doses if needed have been strengthened.

·        Section 4.2 Method of administration - updated to ensure vaccine not injected intravascularly and reference to see section 6.6 for instructions for preparation.

·         Section 4.5 – inclusion of a sentence regarding concomitant administration

·         Section 4.7 – wording change for clarification.

·         Section 5.1 – additional information provided on clinical trials and booster doses.

·         Section 6.2 – wording change for clarification

·         Section 6.6 – inclusion of additional sentence   

        with regards to disposal of waste.

·         Section 10 – update to date of revision of the text

Updated on 20/06/2005 and displayed until 22/08/2006
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text
Updated on 27/04/2005 and displayed until 20/06/2005
Reasons for adding or updating:
  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text
Updated on 23/06/2003 and displayed until 27/04/2005
Reasons for adding or updating:
  • New SPC for medicines.ie

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
   Hepatitis B vaccine (rDNA)

Versions

 
03/10/2011 to Current
20/07/2011 to 03/10/2011
28/11/2008 to 20/07/2011
07/02/2008 to 28/11/2008
22/08/2006 to 07/02/2008
20/06/2005 to 22/08/2006
27/04/2005 to 20/06/2005
23/06/2003 to 27/04/2005
  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo